MYO9

MYO9 is a preclinical small-molecule drug candidate from Myocea being developed for spinal muscular atrophy. The program appears in Myocea's pipeline as an internal SMA discovery candidate directed at \"Network 5,\" a proprietary or undisclosed target network relevant to SMA skeletal muscle and neuromuscular junction biology. Publicly available information does not define the precise molecular target, binding mode, or downstream pharmacology beyond this network-level designation, so the mechanism is best described as an investigational small-molecule modulator of Network 5 for SMA.

Other names

Myocea-Network 5-small molecule-Spinal Muscular AtrophyMyocea-Network5-small molecule-Spinal Muscular AtrophyMyocea-Network-5-small molecule-Spinal Muscular AtrophyMyocea Network 5 small molecule